Poland faces growing Alzheimer’s challenge as neurological conditions emerge as major health concerns alongside cancer and heart disease.
What is Alzheimer’s Disease in Poland?
Alzheimer’s disease accounts for 60-65% of all dementia cases. It is an irreversible process in which brain cells are gradually destroyed. Although it is estimated that 550,000-650,000 people in Poland suffer from dementia (with approximately 470,000 being Alzheimer’s patients), the alarming fact is that only about 18-20% of patients have an official medical diagnosis.
Risk Factors and Age
Statistical data clearly shows that age is the main risk factor for developing Alzheimer’s disease. As the population ages, neurodegenerative conditions, with Alzheimer’s disease (AD) at the forefront, affect more and more families.
Early Warning Signs and Symptoms
In the initial, preclinical phase of Alzheimer’s disease, subtle cognitive impairments may appear that are not always associated with developing dementia. One of the first signals can be a decline in working memory, or difficulty in storing and processing information “here and now.” A person may have problems with tasks requiring planning, logical thinking, or performing several activities simultaneously.
Early symptoms also include executive function impairment, which manifests as difficulty in organizing activities, making decisions, and solving even simple everyday problems. Importantly, these types of changes can occur before clear episodic memory disturbances appear, such as forgetting recent events.
Research also indicates slowed information processing as a potential early marker of Alzheimer’s disease. People in the pre-symptomatic stage may need more time to analyze data, respond to stimuli, or perform cognitive tests.
Among the first symptoms of the disease, social and behavioral changes are also mentioned. Mood deterioration, apathy, withdrawal from social life, and decreased interest in daily activities may appear. Such symptoms are sometimes misinterpreted as fatigue or depression, but in some cases, they constitute one of the early signs of developing neurodegenerative disease.
Diagnosing Alzheimer’s
The disease process in the brain begins many years before the appearance of clear symptoms. Some scientists have indicated that there is a distinct stage of the disease that differs from clinical dementia, which can be detected through biomarkers. At this stage, obvious dementia has not yet occurred, but the brain is already undergoing pathological changes.
Currently, there is no single test that definitively confirms Alzheimer’s. Diagnosis is a complex process that involves excluding other causes. The diagnosis is based on an interview with the patient and their close relatives. A physical examination and assessment of neurological function are also conducted. Diagnostics also includes tests to assess cognitive abilities.
In the diagnostic process in Poland, key examinations are imaging studies: computed tomography (CT) or magnetic resonance imaging (MRI). They allow for the assessment of structural atrophy in the brain and the exclusion of other conditions.
Current Treatment Methods
Currently, medicine does not know a drug that would completely reverse the changes in the brain. However, early diagnosis is key to a better life. There are pharmacological agents available that slow the progression of the disease.
Treatment includes both pharmacological and non-pharmacological approaches.
